Develop innovative & clinically impactful therapies & diagnostics to improve quality of life
I believe the surgiceutical approach to prevent adhesions is a gamechanger in gynecology pelvic surgeries. For me it is important that it is not a barrier or medical devices which are not that effective. Read More
Dr. James Greenberg Vice Chair Obs and Gyne, Brigham and Women's, Harvard Medical School
First Surgiceutical drug candidate modulates post-operative tissue fibrosis to prevent adhesions
TTX 330 is a therapeutic & bioresorbable polymer combination that helps reduce fibrosis in synovial joints
TTX 334e is a novel non-hormonal drug candidate being studied for the treatment of endometriosis.
TTX 335o is a novel targeted therapeutic for range of solid tumors, particularly recurrent, sensitive and platinum resistant cancers
TTX 334Dx translating a novel biomarker into the first non-invasive blood test for diagnosing endometriosis
Chairman, Previous VP International Marketing, Abbott
SVP Business Development, Palatin Technologies
Managing Director, Yorkville Advisors
Sr. Director, US Aortic Stent Graft Programs, CryoLife
CEO, Micron Biomedical, Inc.
Senior Vice President, Legal Affairs and Deputy General Counsel, Emergent BioSolutions
Mexican Businessman and Entrepreneur
Chief Financial Officer, Longboard Pharmaceuticals, Inc.
Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer & Global Medical Lead
Chief Operating Officer
Chief Strategic Counsel
MD, Clinical Advisor
MD, MPH
MD, MSc, PhD
PhD, MD, FRCS
MS, PhD, FEAS, FCAHS
I was lost. I was clueless. And I thought I was alone. The disease that affects 1 in 10 women, had me on my knees, left to feel isolated. 16 years of painful periods, 14 doctors, innumerable appointments, periodic visits to the clinic, numerous blood tests and 100 sonograms & misdiagnosis later, I
Read More
“Evitar™ offers a potential therapeutic option for preventing adhesion formation based on sound scientific principles with the exciting triad of Efficacy, Safety and Ease of Use.”... Read More
Evitar™ provides a totally new pre-emptive concept, that actively intervenes in the molecular pathway of adhesion formation."... Read More
Urmonderbaan 22 (Gate 2) 6167 RD Geleen Netherlands
PO Box 18 6160 MD Geleen Netherlands
info@templerx.com
© 2021 Temple Therapeutics BV. All Rights Reserved
Website Design & Developed by 2Web Design
